Ambrx Shareholders Approve Acquisition by Johnson & Johnson
Ambrx Biopharma, Inc. (AMAM)
Company Research
Source: GlobeNewswire
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O’Connor, Chief Executive Officer of Ambrx, said, “We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in the industry, we have transformed Ambrx and are advancing a promising pipeline unlike anything else in development today. We are thrilled to start this next chapter with Johnson & Johnson as we continue to treat cancers with high unmet needs.” More than 99% of the votes cast at the Special Meeting
Show less
Read more
Impact Snapshot
Event Time:
AMAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMAM alerts
High impacting Ambrx Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
AMAM
News
- Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZBPR Newswire
- AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAMBusiness Wire
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGANGlobeNewswire
- Lifshitz Law PLLC Announces Investigations of AMAM, HARP, AXNX, and FGHAccesswire
AMAM
Sec Filings
- 3/8/24 - Form S-8
- 3/8/24 - Form S-8
- 3/8/24 - Form S-8
- AMAM's page on the SEC website